FAM chemotherapy +/- aminoglutethimide in the treatment of pancreatic carcinoma.

Lipton, A; Harvey, H A; Santen, R J; Stryker, J A; Barnes, S G; Walker, B K; Dixon, R H; Givant, E M; Bartholomew, M J; Nadjafi, C

Lipton, A; Harvey, H A; Santen, R J; Stryker, J A; Barnes, S G; Walker, B K; Dixon, R H; Givant, E M; Bartholomew, M J; Nadjafi, C.

Affiliation

Lipton A; Central Pennsylvania Oncology Group, Hershey 17033.

Eur J Surg Oncol ; 16(1): 12-4, 1990 Feb.

Article in En | MEDLINE | ID: mdl-2307239

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Pancreatic Neoplasms/drug therapy; Aminoglutethimide/administration & dosage; Combined Modality Therapy; Doxorubicin/administration & dosage; Drug Evaluation; Fluorouracil/administration & dosage; Humans; Hydrocortisone/administration & dosage; Mitomycin; Mitomycins/administration & dosage; Pancreatic Neoplasms/mortality; Pancreatic Neoplasms/radiotherapy; Prospective Studies; Random Allocation; Survival Rate

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Pancreatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Humans Language: En Year: 1990 Type: Article

Search on Google

XML

PubMed Links